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Summary
Background.  —  Dual  antiplatelet  therapy,  comprising  aspirin  and  clopidogrel,  is  recommended
in patients  undergoing  coronary  stenting  to  avoid  the  occurrence  of  stent  thrombosis  and  others
ischaemic  events.  Interindividual  response  to  clopidogrel  varies,  however,  with  poor  response
associated  with  an  increased  risk  of  ischaemic  events.  New  assays  are  available  for  testing
aspirin and  clopidogrel  response  routinely  at  the  bedside.
Aim. —  To  evaluate  the  prognostic  value  of  testing  antiplatelet  response  in  an  intermediate-risk
population  undergoing  stent  implantation.
Methods.  —  We  prospectively  assessed  clopidogrel  and  aspirin  response  using  the  VerifyNow
assay at  the  time  of  coronary  stenting  in  1001  patients  who  presented  with  stable  coronary  dis-
ease or  non-ST-segment  elevation  acute  coronary  syndrome.  The  main  ischaemic  endpoint  was
the composite  of  deﬁnite  and  probable  stent  thrombosis,  cardiovascular  death  or  spontaneous
myocardial  infarction  at  one  year.  The  safety  endpoint  was  major  bleeding.
Results.  —  Overall,  36.0%  of  patients  had  high  on-clopidogrel  platelet  reactivity  (OCR)  and  8.6%
had high  on-aspirin  platelet  reactivity  (OAR).  The  main  ischaemic  composite  endpoint  occurred
in 3.9%  of  patients  with  high  vs.  2.3%  of  patients  with  normal  OCR  (hazard  ratio  1.66,  95%
conﬁdence interval  0.78—3.54;  P  =  0.18).  Deﬁnite  or  probable  stent  thrombosis  occurred  in  1.1%
of patients  with  high  vs.  0.3%  of  patients  with  normal  OCR  (P  =  0.86).  There  was  no  signiﬁcant
difference  in  ischaemic  endpoints  according  to  OAR  and  there  was  no  difference  in  rates  of
major bleeding  between  patients  with  high  versus  normal  on-treatment  platelet  reactivity.
Conclusions.  —  On-treatment  platelet  reactivity  was  not  associated  with  1-year  ischaemic  or
bleeding events  in  an  intermediate-risk  population  undergoing  stent  implantation.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Rationnel.  —  La  bithérapie  antiplaquettaire,  comprenant  l’aspirine  et  le  clopidogrel,  est
recommandée  chez  tous  les  patients  après  stenting  coronaire  pour  prévenir  les  évènements
ischémiques  dont  la  thrombose  de  stent.  La  réponse  individuelle  au  clopidogrel  est  très  variable
et une  faible  réponse  est  associée  à  une  augmentation  des  évènements  ischémiques.  De  nou-
veaux tests  sont  maintenant  disponibles  pour  évaluer  cette  réponse  à  l’aspirine  et  au  clopidogrel
de manière  routinière  et  délocalisée.
Objectif.  —  Évaluer  la  valeur  pronostique  de  ces  tests  de  réponse  aux  antiplaquettaires  chez
une population  à  risque  intermédiaire  bénéﬁciant  d’un  stenting  coronaire.
Méthode.  —  Nous  avons  mesuré  de  fac¸on  prospective  la  réponse  à  l’aspirine  et  au  clopidogrel
par VerifyNow  lors  de  la  procédure  de  stenting  coronaire  chez  1001  patients  présentant  un  angor
stable ou  un  syndrome  coronarien  aigu  sans  sus-décalage  du  segment  ST.  Le  critère  compos-
ite principal  d’évaluation  des  événements  ischémiques  était  l’apparition  d’une  thrombose  de
stent certaine  ou  probable  et/ou  d’un  décès  cardio-vasculaire  et/ou  d’un  infarctus  spontané
du myocarde  à  1  an.  Le  critère  d’évaluation  de  sécurité  était  les  saignements  majeurs.
Résultats.  —  Sur  l’ensemble  de  la  population,  36  %  des  patients  gardait  une  hyperréactivité
plaquettaire  sous  clopidogrel  (HPC)  et  8,6  %  gardait  une  hyperréactivité  plaquettaire  sous
aspirine (HPA).  Le  critère  composite  d’évaluation  principal  a  été  observé  dans  3,9  %  des  cas
chez les  patients  avec  hyperréactivité  vs  2,3  %  avec  normoréactivité  plaquettaire  sous  clopid-
ogrel (NPC)(hazard  ratio  1,66,  95  %  intervalle  de  conﬁance  0,78—3,54  ;  p  =  0,18).  La  thrombose
Events  after  stenting  according  to  clopidogrel  and  aspirin  platelet  reactivity  227
de  stent  certaine  ou  probable  a  été  observée  dans  1,1  %  des  HPC  vs  0,3  %  chez  les  NPC  (p  =  0,86).
Il n’a  pas  été  observé  de  différence  signiﬁcative  tant  des  évènements  ischémiques  que  hémor-
ragiques entre  le  groupe  des  hyper-  vs  normorépondeurs  au  traitement  antiplaquettaire.
Conclusion.  — La  réactivité  plaquettaire  sous  clopidogrel  et  aspirine  n’est  pas  corrélée  à
l’incidence  des  évènements  ischémiques  et  hémorragique  à  1  an  d’un  stenting  coronaire  dans
une population  à  risque  intermédiaire.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Dual  antiplatelet  therapy  with  aspirin  and  clopidogrel  is  rec-
ommended  in  patients  undergoing  coronary  stenting  to  avoid
the  occurrence  of  stent  thrombosis  and  ischaemic  events
[1].  Interindividual  response  to  clopidogrel  varies  widely,
however,  due  to  drug-related  factors  and  genetic  mutations,
but  also  to  several  other  clinical  factors  including  diabetes
mellitus,  acute  coronary  syndrome  and  high  body  mass
index  [2].  Several  studies  have  demonstrated  a  relation-
ship  between  clopidogrel  and/or  aspirin  poor  response  and
increased  risk  of  ischaemic  events  after  coronary  stenting
[3—5].  Most  were  performed  using  light  transmission  aggre-
gometry,  an  assay  that  is  not  widely  available  in  practice
due  to  laboratory  constraints.  New  and  reliable  assays  are
now  available  for  testing  aspirin  and  clopidogrel  response
routinely  at  the  bedside,  including  the  VerifyNowTM P2Y12
assay  (Accumetrics,  San  Diego,  CA,  USA)  [6].
The  aim  of  the  multicentre  VerifyNow  French  Registry
(VERIFRENCHY)  was  to  assess  the  prognostic  value  of  testing
on-treatment  platelet  reactivity  using  aspirin  and  clopid-
ogrel  with  the  VerifyNow  assay  at  the  time  of  coronary
stenting.
Methods
Study population
VERIFRENCHY  was  a  multicentre  prospective  observational
study  that  recruited  patients  in  20  high-volume  percuta-
neous  coronary  intervention  (PCI)  centres  in  France.  The
study  population  included  adults  (≥  18  years)  with  stable
angina,  silent  ischaemia  or  non-ST-segment  elevation  acute
coronary  syndrome  (ACS;  unstable  angina  or  non-ST-segment
elevation  myocardial  infarction)  undergoing  planned  PCI
with  stenting.  Exclusion  criteria  were  periprocedural  gly-
coprotein  IIb/IIIa  inhibitors,  bivalirudin  treatment  before
PCI,  contraindications  to  aspirin  or  clopidogrel,  use  of  oral
anticoagulation  and  lack  of  available  clopidogrel  response
at  inclusion.  Written  informed  consent  was  obtained  from
all  patients  before  the  index  procedure.  The  study  was
approved  by  the  French  Authorities  (AFSSAPS  [2008-A00411-
54]  and  CPP  [n◦ 2008-N2]).
Procedures
Eligible  patients  were  screened  at  the  time  of  the  coro-
nary  angiogram.  Patients  were  loaded  with  clopidogrel
600  mg  ≥  two  hours  before  PCI  unless  they  had  been  on  a
maintenance  clopidogrel  dose  of  75  mg  for  >  one  week.  An
intravenous  loading  dose  of  aspirin  was  given  according
i
e
b
io  the  investigators’  usual  practices  in  patients  in  whom
spirin  was  started  <  one  week  before  angiography.  Patients
ere  tested  for  both  aspirin  and  clopidogrel  response  before
tent  implantation.  A  valid  biological  measure  of  clopido-
rel/aspirin  response  was  requested  before  inclusion  in  the
tudy.
After  stent  implantation,  aspirin  (75—160  mg)  and  clo-
idogrel  (75  mg)  maintenance  doses  were  recommended  for
ne  month  after  bare-metal  stent  (BMS)  implantation  and  for
ne  year  after  drug-eluting  stent  (DES)  implantation  or  if  the
linical  presentation  was  an  ACS.  In  this  registry,  we  com-
ared  the  rate  of  primary  and  secondary  endpoints  at  one
ear  according  to  treatment  response  to  both  clopidogrel
nd  aspirin.
Data  were  collected  prospectively  on-site  and  analysed
y  the  Peter  Holmes  Company.  Blood  samples  were  drawn
oth  before  PCI  and  24  hours  after  PCI  to  measure  troponin
oncentrations.  Follow-up  data  were  obtained  by  clinical
xamination  at  hospital  discharge  and  by  telephone  contact
t  one  month  and  one  year  after  discharge.
Whole  blood  was  obtained  at  the  time  of  catheterization.
latelet  function  testing  was  performed  with  the  VerifyNow
ssay  after  the  decision  was  made  to  perform  stenting,
ut  before  starting  PCI  [7,8]. The  selection  of  VerifyNow
latelet  inhibition  (%PI)  with  a  cut-off  of  ≤  15%  was  based
n  data  from  Bouman  et  al.,  who  demonstrated  a  good
orrelation  between  P2Y12  reaction  unit  values  and  %PI
ith  plasma  concentrations  of  active  metabolite  clopidogrel
9]. High  on-aspirin  platelet  reactivity  (OAR)  was  deﬁned
s  an  aspirin  reaction  unit  (ARU)  ≥  550,  and  normal  OAR
as  deﬁned  as  ARU  <  550  [7,8].  High  on-clopidogrel  platelet
eactivity  (OCR)  was  deﬁned  as  %PI  ≤  15%  and  normal  OCR
s  %PI  >  15%,  based  on  data  from  Godino  et  al.  [3].  Investi-
ators  were  strongly  encouraged  not  to  modify  antiplatelet
herapy  according  to  the  results  of  platelet  function  tests.
Patients  were  also  classiﬁed  according  to  the  VerifyNow
PI  and  ARU  quartiles  to  assess  bleeding  events;  the  lowest
latelet  reactivity  quartiles  of  clopidogrel  and  aspirin  were
ompared  with  the  other  three  quartiles.
ndpoints
schaemic  endpoints  were  deﬁned  as  deﬁnite  and  proba-
le  stent  thrombosis,  myocardial  infarction  (spontaneous
nd/or  periprocedural),  all-cause  death,  cardiovascular
eath  and  stroke.  The  main  ischaemic  composite  endpoint
as  a  combination  of  deﬁnite  and  probable  stent  throm-
osis,  cardiovascular  death  and  spontaneous  myocardial
nfarction  at  one  year.  The  secondary  composite  ischaemic
ndpoint  included  the  combination  of  deﬁnite  and  proba-
le  stent  thrombosis,  all-cause  death,  non-fatal  myocardial
nfarction  (spontaneous  and  periprocedural)  and  stroke.
2 G.  Rangé  et  al.
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Figure 1. Study ﬂow chart. %PI: percentage of platelet inhi-
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Periprocedural  myocardial  infarction  was  deﬁned  as  a
ostprocedural  increase  in  troponin  concentration  >  three
imes  the  99th  percentile  upper  reference  limit  in  patients
ith  normal  baseline  concentrations  of  troponin  (type  4a
10]);  in  patients  with  an  ACS  and  raised  baseline  troponin
oncentrations,  the  deﬁnition  of  a  subsequent  elevation
 20%  of  the  baseline  value  was  applied  [11]. Sponta-
eous  myocardial  infarction  was  deﬁned  as  ≥  1  value  of
roponin  >  99th  percentile  upper  reference  limit  together
ith  evidence  of  myocardial  ischaemia  (type  1)  [10,11].
tent  thrombosis  included  deﬁnite,  probable  and  possible
tent  thrombosis  [11].  Ischaemic  stroke  was  deﬁned  as  focal
oss  of  neurological  function  caused  by  an  ischaemic  event.
The  main  safety  endpoint  was  deﬁned  according  to
he  International  Society  of  Thrombosis  and  Haemostasis
eﬁnitions  [12].  Major  bleeding  was  deﬁned  as:  fatal  bleed-
ng;  symptomatic  bleeding  in  a  critical  area  or  organ  (i.e.
ntracranial,  intraspinal,  intraocular,  retroperitoneal,  intra-
rticular  or  pericardial),  or  intramuscular  bleeding  with
ompartment  syndrome;  and  bleeding  causing  a  fall  in
aemoglobin  concentration  of  ≥  20  g/L  or  leading  to  trans-
usion  of  ≥  two  units  of  whole  blood.  Minor  bleeding  was
eﬁned  as  any  clinically  overt  sign  of  haemorrhage  that  was
ctionable,  but  did  not  meet  the  criteria  for  major  bleeding.
tatistical analysis
 power  calculation  was  performed  to  determine  the  study
ample  size.  Anticipating  a  35%  rate  of  high  OCR  and  an
nnual  stent  thrombosis  rate  of  1.7%  [13]  (  risk  at  5%  and
rror  at  80%,  bilateral  test),  800  patients  would  be  needed;
llowing  for  loss  to  follow-up,  a  population  of  1000  patients
as  chosen.
Continuous  variables  and  categorical  variables  are
xpressed  as  mean  ±  standard  deviations  and  counts  and
ercentages,  respectively.  Student’s  t  test  was  used  to
ompare  continuous  variables  and  the  Chi2 test  or  Fisher’s
xact  test  was  used  to  compare  categorical  variables.  Sur-
ival  analysis  was  performed  by  the  Kaplan—Meier  method
ith  a  log-rank  test-group  comparison.  A  P  value  <  0.05  was
onsidered  statistically  signiﬁcant.  Statistical  analysis  was
erformed  using  SPSS  version  20.0  (IBM  Corp,  Somers,  NY,
SA).
esults
 total  of  1053  patients  were  pre-treated  with  clopidogrel
nd  aspirin  and  underwent  PCI  with  stenting.  A  VerifyNow
est  result  was  not  available  in  52  (4.9%)  patients  due  to
echnical  issues  (bubbling  or  calibration  problem);  conse-
uently,  1001  patients  were  included  in  the  analysis.  In  29
2.9%)  of  these  patients,  the  aspirin  test  result  was  not
vailable;  therefore  972  patients  were  included  in  the  com-
arison  of  aspirin  response  (Fig.  1).  Among  the  1001  patients
ith  P2Y12  VerifyNow  test  results  available,  360  (36.0%)  had
igh  OCR  and  641  (64.0%)  had  normal  OCR.  Among  the  972
atients  with  aspirin  test  results  available,  84  (8.6%)  had
igh  OAR  and  888  (91.4%)  had  normal  OAR.
Patients  with  high  OCR  were  on  average  older,  had  a
igher  body  mass  index,  were  more  often  diabetic  and  less
requently  smokers  compared  to  patients  with  normal  OCR
9
c
pition; ARU: aspirin reaction units; BMS: bare-metal stent; DES:
rug-eluting stent; PCI: percutaneous coronary intervention.
Table  1).  High  OAR  patients  were  more  frequently  men  and
isplayed  a  higher  creatinine  clearance  than  patients  with
ormal  OAR.
No  differences  were  observed  in  the  angiographic  and
rocedural  characteristics  between  high  and  normal  OCR
atients,  except  for  less  frequent  use  of  DES  in  high  OCR
atients  (Table  2).  Despite  strong  recommendations  not  to
hange  treatment,  patients  with  high  OCR  were  more  fre-
uently  given  glycoprotein  IIb/IIIa  inhibitors  and  reloaded
ith  clopidogrel  during  the  post-PCI  period  compared  with
hose  with  normal  OCR.  In  addition,  almost  one-quarter  of
he  patients  had  a  double  maintenance  clopidogrel  dose  at
ischarge  from  hospital,  with  no  statistically  signiﬁcant  dif-
erence  between  the  high  versus  normal  platelet  reactivity
roups  (Table  2).
At 1-year  follow-up,  the  main  ischaemic  composite  end-
oint  occurred  in  3.9%  of  patients  with  high  vs.  2.3%  of  those
ith  normal  OCR  (hazard  ratio  [HR]  1.66,  95%  conﬁdence
nterval  [CI]  0.78—3.54;  log  rank  P  =  0.18)  (Fig.  2A),  while  the
econdary  ischaemic  composite  endpoint  occurred  in  15.8%
f  patients  with  high  vs.  18.6%  with  normal  OCR  (HR  0.84,
5%  CI  0.61—1.16;  log  rank  P  =  0.25)  (Fig.  2B).
Ten  cases  of  stent  thrombosis  occurred  (1.0%  of  the  whole
ohort),  of  which  two  were  deﬁnite,  four  probable  and  four
ossible  (Table  3).  Deﬁnite  and  probable  stent  thrombosis
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Table  1  Patient  baseline  characteristics.
Variables  On-clopidogrel  platelet  reactivity  On-aspirin  platelet  reactivity
Total
cohort
n  =  1001)
High
(n  =  360)
Normal
(n  =  641)
P  Total
cohort
(n  =  972)
High
(n  =  84)
Normal
(n  =  888)
P
Age  (years)  66.5  ±  11.4  68.3  ±  11.6  65.5  ±  11.2  <  0.001  66.6  ±  11.5  66.1  ±  12.4  66.6  ±  11.4  0.69
Men  833  (83.2)  298  (82.8)  535  (83.5)  0.78  809  (83.2)  78  (92.9)  731  (82.3)  0.01
Body  mass  index
(kg/m2)
26.5  ±  4.0  27.2  ±  4.4  26.2  ±  3.7  <  0.001  26.5  ±  4.1  27.0  ±  4.2  26.5  ±  4.0  0.30
Current  smoker  181  (18.1)  49  (13.6)  132  (20.6)  0.02  177  (18.2)  17  (20.2)  160  (18.0)  0.38
Hypertension  594  (59.3)  223  (61.9)  371  (57.9)  0.20  579  (59.6)  51  (60.7)  528  (59.5)  0.80
Family  history 312  (31.2) 100  (27.8) 212  (33.1)  0.08  304  (31.3)  21  (25.0)  283  (31.9)  0.19
Diabetes  mellitus  261  (26.1)  127  (35.3)  134  (20.9)  <  0.001  249  (25.6)  23  (27.4)  226  (25.5)  0.69
Hypercholesterolemia  665  (66.4)  227  (63.1)  438  (68.3)  0.09  649  (66.8)  52  (61.9)  597  (67.2)  0.33
Creatinine  clearance
(mL/min/m2)
81.8  ±  31.2  79.5  ±  31.3  83.1  ±  31.1  0.08  81.6  ±  31.0  88.1  ±  32.5  81.0  ±  30.8  0.04
Acute  coronary
syndromes
216 (21.6)  82  (22.8)  134  (20.9)  0.49  208  (21.4)  16  (19.0)  192  (21.6)  0.58
f
i
(
DData are mean ± standard deviation or number (%).
occurred  in  1.1%  of  patients  with  high  vs.  0.3%  with  normal
OCR  (log  rank  P  =  0.86).  None  of  the  84  patients  with  high
OAR  had  stent  thrombosis  vs.  0.7%  of  patients  in  the  normal
OAR  group  (P  =  0.58)  (Table  4).  No  differences  were  observed
in  the  rates  of  other  ischaemic  or  bleeding  events  according
to  OCR  or  OAR  (Table  4).No  differences  were  found  in  the  rates  of  major  bleeding
between  the  OCR  or  OAR  quartiles  (Table  5).  The  rates  of
minor  bleeding  were  greater  in  the  highest  quartiles  of  OCR
and  OAR,  but  the  difference  was  statistically  signiﬁcant  only
I
c
g
Figure 2. Cumulative incidence of the (A) primarya and (B) seconda
high on-treatment platelet reactivity as measured by the VerifyNow P2Y
ratio; OCR: on-clopidogrel platelet reactivity. aComposite of cardiovasc
myocardial infarction. bComposite of deﬁnite and probable stent thro
myocardial infarction.or  OAR  (P  =  0.002).  Conversely  and  of  interest,  major  bleed-
ng  was  decreased  by  threefold  in  the  top  quartile  of  OCR
Table  5).
iscussionn  this  multicentre  French  registry  of  patients  with  stable
oronary  disease  or  non-ST-segment  elevation  ACS  under-
oing  planned  PCI  with  stenting  and  pre-treated  with
ryb combined ischaemic outcomes in patients with and without
12 assay at 1-year follow-up. CI: conﬁdence interval; HR: hazard
ular death, deﬁnite and probable stent thrombosis, spontaneous
mbosis, all-cause death, spontaneous, stroke and periprocedural
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Table  2  Angiographic  and  procedural  characteristics.
Variable  On-clopidogrel  platelet  reactivity  On-aspirin  platelet  reactivity
Total
cohort
(n  =  1001)
High
(n  =  360)
Normal
(n  =  641)
P  Total
cohort
(n  =  972)
High
(n  =  84)
Normal
(n  =  888)
P
Radial  access  767  (76.6)  279  (77.5)  488  (76.1)  0.88  745  (76.6)  67  (79.8)  678  (76.4)  0.86
Number  of  diseased
vessels
One  434  (43.4)  155  (43.1)  279  (43.5)  0.88  423  (43.5)  40  (47.6)  383  (43.1)  0.43
Two  345  (34.5)  114  (31.7)  231  (36.0)  0.16  329  (33.8)  20  (23.8)  309  (34.8)  0.04
Three  199  (19.9)  81  (22.5)  118  (18.4)  0.12  197  (20.3)  23  (27.4)  174  (19.6)  0.09
Left  main  disease 32  (3.2) 11  (3.1) 21  (3.3)  0.85  32  (3.3)  2  (2.4)  30  (3.4)  0.62
Number  of  lesions
per  patient
1.3  ±  0.5  1.3  ±  0.5  1.3  ±  0.6  0.26  1.3  ±  0.5  1.3  ±  0.6  1.3  ±  0.5  0.79
Lesion  type  B2/C  573  (57.2)  199  (55.2)  374  (58.3)  0.68  559  (57.5)  51  (60.7)  508  (57.2)  0.53
Thrombus-
containing
lesion
42  (4.2)  19  (5.3)  23  (3.6)  0.20  42  (4.3)  5  (6.0)  37  (4.2)  0.40
Number  of  vessels
treated  per
patient
1.2 ±  0.4 1.2  ±  0.4 1.2  ±  0.4  0.11  1.2  ±  0.4  1.2  ±  0.4  1.2  ±  0.4  0.99
Number  of  stents
per  patient
1.5  ±  0.8  1.5  ±  0.8  1.5  ±  0.8  0.68  1.5  ±  0.8  1.5  ±  0.7  1.5  ±  0.8  0.55
At  least  one
DES/patient
573  (57.2)  190  (52.8)  383  (59.8)  0.03  557  (57.3)  44  (52.4)  513  (57.8)  0.34
Minimal  stent
diameter  (mm)
3.7 ±  16.2  3.9  ±  18.6  3.6  ±  14.7  0.76  3.7  ±  16.5  2.9  ±  0.5  3.8  ±  17.2  0.63
Maximal  length  of
stent  (mm)
21.7  ±  12.4  22.0  ±  14.9  21.5  ±  10.7  0.61  21.6  ±  12.4  23.2  ±  21.7  21.5  ±  11.1  0.47
Thrombectomy  6  (0.6)  4  (1.1)  2  (0.3)  0.19  5  (0.5)  0  5  (0.6)  0.49
Rotablator  10  (1.0)  1  (0.3)  9  (1.4)  0.10  9  (0.9)  0  9  (1.0)  0.35
Post  stent  inﬂation  208  (20.8)  78  (21.7)  130  (20.3)  0.60  202  (20.2)  14  (16.7)  188  (21.2)  0.33
GPI  peri  or  post  PCI  42  (4.2)  18  (5.0)  24  (3.7)  0.05  42  (4.3)  4  (4.8)  38  (4.3)  0.83
GPI  reloading  dose
post  PCI
92  (9.2)  55  (15.3)  37  (5.8)  <  0.001  90  (9.3)  16  (19.0)  74  (8.3)  0.001
Clopidogrel
maintenance
regimen  post  PCI
75  mg  776  (77.5)  273  (75.8)  503  (78.5)  0.33  754  (77.6)  63  (75)  691  (77.8)  0.55
≥  150  mg  225  (22.5)  87  (24.2)  138  (21.5)  0.33  218  (22.4)  21  (25.0)  197  (22.2)  0.55
Data are mean ± standard deviation or number (%). DES: drug-eluting stent; GPI: glycoprotein IIb/IIIa inhibitor; PCI: percutaneous
coronary intervention.
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tlopidogrel  and  aspirin,  the  1-year  rate  of  ischaemic  and
ajor  bleeding  events  did  not  differ  according  to  residual
latelet  reactivity.
The  analytical  validity  of  the  VerifyNow  assay  in  com-
arison  with  light  transmission  aggregometry  has  been
emonstrated  in  previous  investigations  [14,15].  The  results
rom  several  studies  (Table  6)  [16—21]  and  a  meta-analysis
22]  have  suggested  that  the  level  of  on-treatment  platelet
eactivity  according  to  the  VerifyNow  assay  is  associated
ith  cardiovascular  events,  including  stent  thrombosis,
fter  PCI.  Randomized  clinical  trials  have,  however,
rovided  controversial  ﬁndings  on  adjusting  antiplatelet
herapy  on  the  basis  of  on-treatment  platelet  reactivity
esults.  The  ARCTIC  study  reported  no  improvement  in
S
s
c
rlinical  outcomes  with  platelet  function  monitoring  and
reatment  adjustment  for  coronary  stenting  using  the  Ver-
fyNow  assay  [23].  In  the  GRAVITAS  study,  the  use  of
igh-dose  versus  standard-dose  clopidogrel  in  patients  with
igh  on-treatment  reactivity  after  PCI  with  DES  did  not
educe  the  incidence  of  ischaemic  events  [24].  Also,  the
RIGGER-PCI  study  was  interrupted  prematurely  due  to  futil-
ty  (low  number  of  cardiac  deaths  or  myocardial  infarctions)
25]. Finally,  the  TRILOGY  study,  one  of  the  largest  recent
rials  of  patients  with  medically  managed  ACS  without
T-segment  elevation,  also  found  no  signiﬁcant  relation-
hip  between  the  occurrence  of  ischaemic  events  and
ontinuous  P2Y12  reaction  unit  (PRU)  values  [26].  The
esults  of  these  randomized  trials  bring  into  question  the
Events
 after
 stenting
 according
 to
 clopidogrel
 and
 aspirin
 platelet
 reactivity
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Table  3 Characteristics  of  patients  with  deﬁnite,  probable  or  possible  stent  thrombosis.
Stent  thrombosis
category
PRU  value
(%PI)
ARU  value Clinical
presentation
Stent  type  Pre-treatment
interval
Time  to  stent
thrombosis  (days
after  PCI)
Stent thrombosis  presentation
Deﬁnite  stent
thrombosis
Patient  1  (male,
53  years)
284 (14) 414  Post  MI DES  <  48  hours 11  Angiographically  proven
Patient  2  (male,
59  years)
431 (0) 511  ACS  (NSTEMI) DES  <  48  hours 2  Angiographically  proven
Probable  stent
thrombosis
Patient  3  (male,
40  years)
244 (24) 442  Post  MI BMS  <  1  week 4  Unexplained  sudden  death
Patient  4  (male,
22  years)
214 (0) 10  Post  MI DES  >  1  week 15  Unexplained  sudden  death
Patient  5  (male,
62  years)
371 (3)  491  Silent
ischaemia
DES  <  48  hours  159  Documented  MI  in  the  territory
of  the  implanted  stent  without
angiographic  conﬁrmation
Patient  6  (male,
85  years)
219 (40)  409  ACS  (unstable
angina)
DES  >  1  week  53  Documented  MI  in  the  territory
of  the  implanted  stent  without
angiographic  conﬁrmation
Possible  stent
thrombosis
Patient  7  (male,
84  years)
427 (46)  418  Stable  angina  BMS  >  1  week  72  Unexplained  sudden  death
Patient  8  (female,
75  years)
284 (25)  525  Stable  angina  DES  5  days  82  Unexplained  sudden  death
Patient  9  (male,
80  years)
356  (0)  520  Stable  angina  DES  >  1  week  50  Unexplained  sudden  death
Patient  10  (male,
85  years)
374 (0) 546  Unstable
angina
DES  >  1  week  327  Unexplained  sudden  death
%PI: percentage of platelet inhibition; ACS: acute coronary syndrome; ARU: aspirin reaction units; BMS: bare-metal stent; DES: drug-eluting stent; MI: myocardial infarction; NSTEMI:
non-ST-segment elevation myocardial infarction; PRU: P2Y12 reaction units.
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Table  4  Clinical  outcomes  at  1-year  follow-up.
Endpoints  On-clopidogrel  platelet  reactivity  On-aspirin  platelet  reactivity
Total
cohort
(n  =  1001)
High
(n  =  360)
Normal
(n  =  641)
Pa Total
cohort
(n  =  972)
High
(n  =  84)
Normal
(n  =  888)
Pa
Ischaemic  endpoints
Deﬁnite  and  probable  ST  6  (0.6)  4  (1.1)  2  (0.3)  0.86  6  (0.6)  0  6  (0.7)  0.58
Deﬁnite,  probable  and
possible  ST
10  (1.0)  6  (1.7)  4  (0.6)  0.80  10  (1.0)  0  10  (1.1)  0.40
All-cause  death  18  (1.8)  10  (2.8)  8  (1.2)  0.28  18  (1.8)  1  (1.2)  17  (1.9)  0.27
Cardiovascular  death  11  (1.1)  5  (1.4)  6  (0.9)  0.57  11  (1.1)  1  (1.2)  10  (1.1)  0.35
MI  (ESC  type  1) 18  (1.8)  7  (1.9)  11  (1.7)  0.36  17  (1.7)  1  (1.2)  16  (1.8)  0.88
MI  (ESC  type  4a)  149  (14.9)  45  (12.5)  104  (16.2)  0.11  145  (14.9)  8  (9.5)  137  (15.4)  0.15
MI  (types  1  and  4a)  165  (16.5)  50  (13.9)  115  (17.9)  0.17  160  (16.5)  8  (9.5)  152  (17.1)  0.08
Stroke  5  (0.5)  3  (0.83)  2  (0.31)  0.35  4  (0.41)  0  4  (0.45)  0.69
Main  ischaemic  composite
endpointb
29  (2.9)  14  (3.9)  15  (2.3)  0.18  28  (2.9)  2  (2.4)  26  (2.9)  0.87
Secondary  ischaemic
composite  endpointc
176  (17.6) 57  (15.8)  119  (18.6)  0.25  171  (17.6)  8  (9.5)  163  (18.4)  0.05
Safety  endpoints
Major  haemorrhage 11  (1.1) 3  (0.8) 8  (1.2) 0.70  11  (1.1)  0  11  (1.2)  0.37
Minor  haemorrhage 61  (6.1) 15  (4.2) 46  (7.2)  0.94  61  (6.3)  1  (1.2)  60  (6.7)  0.20
Major  and  minor
haemorrhage
72 (7.2) 18  (5.0) 54  (8.4) 0.92  72  (7.4)  1  (1.2)  71  (8.0)  0.13
Data are number (%). ESC: European Society of Cardiology; MI: myocardial infarction; ST: stent thrombosis.
a Log-rank P-value.
b Cardiovascular death, stent thrombosis, MI ESC type 1.
c All-cause death, stent thrombosis, MI ESC types 1 and 4a, stroke.
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televance  of  research  into  antiplatelet  therapy  resistance
n  ACS.
Previous  studies  on  the  prognostic  value  of  the  VerifyNow
ssay  found  an  association  between  high  on-platelet  reac-
ivity  and  clinical  outcomes,  and  reported  higher  rates  of
schaemic  events  than  in  the  VERIFRENCHY  study.  In  the
tudy  by  Price  et  al.  [20],  the  rate  of  deﬁnite  or  proba-
le  stent  thrombosis  was  1.6%  (vs  0.6%  in  VERIFRENCHY);
reet  et  al.  [16]  reported  a  rate  of  spontaneous  myocar-
ial  infarction  of  7.1%  (vs.  1.8%  in  VERIFRENCHY);  and  in
he  study  by  Marcucci  et  al.  [18],  the  rate  of  cardiovas-
ular  deaths  was  3.5%  (vs.  1.1%  in  VERIFRENCHY).  There
re  several  possible  reasons  for  these  discrepancies.  First,
g
o
p
Table  5  Haemorrhagic  events  at  one1  year  according  to  quar
Haemorrhagic  events  On-clopidogrel  platelet  reactivity  
Total
cohort
(n  =  1001)
Q1—Q3
(n =  749)
Q4 high
response
(n =  252)
All  haemorrhage  72  (7.2)  50  (6.7)  22  (8.7)  
Major  haemorrhage  11  (1.1)  10  (1.3)  1  (0.4)  
Minor  haemorrhage  61  (6.1)  40  (5.3)  21  (8.3)  
Data are number (%). Q: quartile.
a Log-rank p-value.nly  22%  of  the  VERIFRENCHY  population  was  diagnosed  with
CS  at  presentation,  a  condition  associated  with  a  threefold
igher  rate  of  stent  thrombosis  compared  with  that  in  a  sta-
le  coronary  artery  disease  population  undergoing  PCI  [27].
ndeed,  the  recent  ADAPT-DES  study  showed  a  correlation
etween  high  OCR  and  ischaemic  events  in  ACS  patients,
hereas  no  such  effect  was  present  in  those  with  a  stable
linical  presentation  [28].  Second,  we  may  have  excluded
igh-risk  procedures,  a  selection  bias  that  may  account  for
he  low  rate  of  ischaemic  events.  Third,  systematic  clopido-
rel  pre-treatment  and  high  rates  of  use  of  a  double  dose
f  clopidogrel  after  hospital  discharge  (22.5%)  may  have
revented  the  development  of  acute  and  subacute  stent
tile  of  response  to  clopidogrel  or  aspirin.
On-aspirin  platelet  reactivity
Pa Total
cohort
(n  =  972)
Q1—Q3
(n =  719)
Q4  high
response
(n =  253)
Pa
0.28  72  (7.4)  44  (6.1)  28  (11.1)  0.01
0.19  11  (1.1)  9  (1.3)  2 (0.8)  0.42
0.09  61  (6.3)  35  (4.9)  26  (10.3)  0.002
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Table  6  Outcomes  with  the  VerifyNow  assay.
Studies  ACS  (%)  Cut-off  High  on-clopidogrel
platelet  reactivity  (%)
Endpoints:  high  vs.  normal
on-clopidogrel  platelet  reactivity
Price  et  al.,  2008  [20]  6.3  PRU  >  235  34.1  CV  death:  2.8%  vs.  0%  (P  =  0.004)
ST:  4.6%  vs.  0%  (P  =  0.004)
Composite  of  CV  death/MI/ST:  6.5%
vs.  1.0%  (P  =  0.008)
Breet  et  al.,  2010  [16] 0  PRU  >  236 38.6  ST:  2.0%  vs.  0.8%  (P  =  0.09)
CV  death:  2.2%  vs.  1.4%  (P  =  0.32)
Patti  et  al.,  2008  [19]  54.4  PRU  >  240  —  Composite  of  CV  death/MI1/TVR:
20%  vs.  3%  (P  =  0.034)
Campo  et  al.,  2010  [17]  32.5  %PI  <  40%  38.2  Death:  2.2%  vs.  1.7%  (P  =  0.4)
Stroke:  1.1%  vs.  0%  (P  =  0.2)
MI1:  4.5%  vs.  16.2%  (P  =  0.001)
Marcucci  et  al.,  2009  [18]  100  PRU  >  240  32.1  CV  death:  3.5%;  HR:  2.38  (P  =  0.031)
MI1:  3.9%;  HR:  2.73  (P  =  0.006)
Suh  et  al.,  2011  [21]  38  PRU  >  252  —  ST:  0.87%
Composite  of  CV  death/ST/MI/TVR:
11.8%  vs.  7.1%  (P  =  0.03)
This  study  21.6  %PI  <  15%  36  ST:  1.1%  vs.  0.3%  (P  =  0.86)
(VERIFRENCHY)  MI1:  1.9%  vs.  1.7%  (P  =  0.36)
Composite  of  ST/CV  death/MI:  3.9%
vs.  2.3%  (P  =  0.18)
%PI: percentage of platelet inhibition; ACS: acute coronary syndrome; CV: cardiovascular; HR: hazard ratio; MI: myocardial infarction
type 1; PRU: P2Y12 reaction units; ST: stent thrombosis; TVR: target vessel revascularization.
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cthrombosis  [29].  Fourth,  recent  improvements  in  techni-
cal  procedures  associated  with  PCI,  such  as  high  pressure
deployment  and  advances  in  stent  conﬁguration,  have  been
associated  with  lower  rates  of  stent  thrombosis  [23]  (ran-
ging  from  1.3  to  1.7%  in  2005  [13],  when  the  ﬁrst  DES  were
introduced,  compared  with  0—0.6%  in  2011,  with  the  intro-
duction  of  second-generation  DES  [24,25]).  The  low  rate  of
ischaemic  events  in  the  present  study  is  similar  to  those
found  in  the  no-monitoring  groups  of  other  studies  [23—25].
The  cut-off  level  used  may  possibly  explain  the  negative
results  of  this  study;  however,  to  date,  there  is  no  consensus
on  this  issue.  The  results  of  the  GRAVITAS  [24]  and  TRIGGER-
PCI  [25]  studies  were  negative  using  cut-off  PRU  values  of
230  and  208,  respectively,  while  ARCTIC  reported  the  same
results  with  a  PRU  cut-off  of  235  and  15%  for  the  %PI  [23].
The  ongoing  ANTARCTIC  study  (NCT01538446)  is  expected  to
provide  more  consistent  answers  in  patients  with  an  ACS.
While  the  results  of  one  study  reported  an  increased  rate
of  major  bleeding  in  clopidogrel  high  responders  [30],  this
ﬁnding  was  not  supported  by  our  results.  The  absence  of
an  increase  in  major  bleeding  observed  in  clopidogrel  good
responders  may  be  due  to  the  high  rate  of  use  of  radial
access  in  the  study,  which  is  associated  with  a  very  low
incidence  of  major  bleeding  [31].
This  study  has  some  limitations.  Higher  rates  of  use  of
a  clopidogrel  reloading  dose  and  of  glycoprotein  IIb/IIIa
inhibitors  in  patients  with  high  OCR  may  have  introduced
bias,  with  the  potential  to  reduce  the  difference  between
event  rates  between  high  and  low  OCR  groups.
The  rate  of  high  on-treatment  platelet  reactivity  to
adenosine  diphosphate  could  be  partially  explained  by
authorization  of  a  600  mg  clopidogrel  loading  dose  two  hours
A
T
mefore  PCI,  as  supported  by  data  from  the  ALBION  study
32]. In  our  study,  however,  74.4%  of  patients  were  treated
 48  hours  before  PCI  and  54.3%  were  treated  >  one  week
efore  PCI.  When  the  study  was  designed  there  was  no
greement  on  the  optimal  cut-off  for  detecting  bleeding
vents;  recently,  however,  there  has  been  a  trend  towards
electing  a  cut-off  of  ≤85  PRU,  based  on  data  from  the  study
y  Campo  et  al.  [33].
onclusions
n  this  prospective  multicentre  study,  on-treatment  platelet
eactivity  using  aspirin  and  clopidogrel  was  not  associated
ith  1-year  ischaemic  or  bleeding  events  in  an  intermediate-
isk  population  undergoing  stent  implantation.  These  results
ay  either  accurately  reﬂect  the  lower  than  expected  event
ates;  conversely,  the  VerifyNow  assay  may  be  unable  to  dis-
inguish  patients  undergoing  coronary  stenting  at  increased
isk  of  an  ischaemic  event.
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